BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 23619251)

  • 1. Probiotics in non-alcoholic fatty liver disease: which and when.
    Abenavoli L; Scarpellini E; Rouabhia S; Balsano C; Luzza F
    Ann Hepatol; 2013; 12(3):357-63. PubMed ID: 23619251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.
    Paolella G; Mandato C; Pierri L; Poeta M; Di Stasi M; Vajro P
    World J Gastroenterol; 2014 Nov; 20(42):15518-31. PubMed ID: 25400436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease.
    Miura K; Ohnishi H
    World J Gastroenterol; 2014 Jun; 20(23):7381-91. PubMed ID: 24966608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gut-liver axis and microbiota in NAFLD: insight pathophysiology for novel therapeutic target.
    Miele L; Marrone G; Lauritano C; Cefalo C; Gasbarrini A; Day C; Grieco A
    Curr Pharm Des; 2013; 19(29):5314-24. PubMed ID: 23432669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic fatty liver disease: for better or worse, blame the gut microbiota?
    Li DY; Yang M; Edwards S; Ye SQ
    JPEN J Parenter Enteral Nutr; 2013 Nov; 37(6):787-93. PubMed ID: 23538296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut microbiota and non-alcoholic fatty liver disease.
    Gkolfakis P; Dimitriadis G; Triantafyllou K
    Hepatobiliary Pancreat Dis Int; 2015 Dec; 14(6):572-81. PubMed ID: 26663004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis.
    Ma YY; Li L; Yu CH; Shen Z; Chen LH; Li YM
    World J Gastroenterol; 2013 Oct; 19(40):6911-8. PubMed ID: 24187469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of the gut microbiota in nonalcoholic fatty liver disease.
    Abu-Shanab A; Quigley EM
    Nat Rev Gastroenterol Hepatol; 2010 Dec; 7(12):691-701. PubMed ID: 21045794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gut microbiota and liver diseases.
    Minemura M; Shimizu Y
    World J Gastroenterol; 2015 Feb; 21(6):1691-702. PubMed ID: 25684933
    [TBL] [Abstract][Full Text] [Related]  

  • 10.  Gut microbiota and nonalcoholic fatty liver disease.
    Machado MV; Cortez-Pinto H
    Ann Hepatol; 2012; 11(4):440-9. PubMed ID: 22700625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of Probiotics (MCP
    Mohamad Nor MH; Ayob N; Mokhtar NM; Raja Ali RA; Tan GC; Wong Z; Shafiee NH; Wong YP; Mustangin M; Nawawi KNM
    Nutrients; 2021 Sep; 13(9):. PubMed ID: 34579068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
    Suk KT; Kim DJ
    Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
    Arab JP; Martin-Mateos RM; Shah VH
    Hepatol Int; 2018 Feb; 12(Suppl 1):24-33. PubMed ID: 28550391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics.
    Solga SF; Diehl AM
    J Hepatol; 2003 May; 38(5):681-7. PubMed ID: 12713883
    [No Abstract]   [Full Text] [Related]  

  • 15. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.
    Koopman N; Molinaro A; Nieuwdorp M; Holleboom AG
    Aliment Pharmacol Ther; 2019 Sep; 50(6):628-639. PubMed ID: 31373710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gut microbiota and host metabolism in liver cirrhosis.
    Usami M; Miyoshi M; Yamashita H
    World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obesity and NAFLD: the role of bacteria and microbiota.
    Duseja A; Chawla YK
    Clin Liver Dis; 2014 Feb; 18(1):59-71. PubMed ID: 24274865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probiotics in the treatment of the liver diseases.
    Kirpich IA; McClain CJ
    J Am Coll Nutr; 2012 Feb; 31(1):14-23. PubMed ID: 22661622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia.
    Xue L; He J; Gao N; Lu X; Li M; Wu X; Liu Z; Jin Y; Liu J; Xu J; Geng Y
    Sci Rep; 2017 Mar; 7():45176. PubMed ID: 28349964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prebiotics and Probiotics: Therapeutic Tools for Nonalcoholic Fatty Liver Disease.
    Mijangos-Trejo A; Nuño-Lambarri N; Barbero-Becerra V; Uribe-Esquivel M; Vidal-Cevallos P; Chávez-Tapia N
    Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.